GlassScriptPhysician profile
Stephen Weinroth
NPI 1033130430
$157,140.32
in general payments reported to CMS, 2019-2025
29 companies · $28K in 2025
The $28K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $921 · 2021: $14K · 2022: $29K · 2023: $33K · 2024: $25K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Honoraria: $9,750 · Travel and Lodging: $9,745 · Food and Beverage: $8,503 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,775.00 |
| Honoraria | $9,750.00 |
| Travel and Lodging | $9,745.14 |
| Food and Beverage | $8,502.64 |
| Education | $104.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $68,302.31 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Gilead Sciences, INC. | $44,381.22 | 2019-2025 | Biktarvy, Sunlenca |
| Theratechnologies INC. | $34,105.88 | 2019-2025 | Trogarzo, Egrifta |
| Viiv Healthcare Company | $5,018.25 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $958.31 | 2019-2025 | Zerbaxa, Dificid, Pifeltro |
| Insmed, INC. | $676.98 | 2019-2025 | Arikayce |
| Abbvie INC. | $478.09 | 2021-2025 | Avycaz, Teflaro, Dalvance |
| Shionogi INC | $456.04 | 2021-2025 | Fetroja |
| Napo Pharmaceuticals INC | $424.58 | 2019-2025 | Mytesi |
| Janssen Biotech, INC. | $391.25 | 2019-2023 | Symtuza |
| Pfizer INC. | $295.14 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $290.00 | 2022-2025 | Rebyota |
| La Jolla Pharmaceutical Company | $200.96 | 2022-2025 | Xacduro, Zevtera, Xerava |
| Janssen Products, LP | $198.00 | 2019-2020 | |
| Astellas Pharma US INC | $177.21 | 2019-2025 | Cresemba |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $136.14 | 2021-2022 | |
| Evoke Pharma, INC. | $125.00 | 2025 | |
| Allergan, INC. | $118.28 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $86.19 | 2019-2023 | Nuzyra |
| Smith+Nephew, INC. | $60.91 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $54.10 | 2024-2025 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $48.28 | 2022-2023 | Hyqvia |
| Dynavax Technologies Corporation | $33.35 | 2021 | |
| Oxford Immunotec USA INC | $27.01 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.90 | 2020 | |
| Pharming Healthcare, INC. | $22.08 | 2024 | Ruconest |
| Horizon Therapeutics Plc | $17.37 | 2022 | |
| Janssen Scientific Affairs, LLC | $17.04 | 2021 | |
| Glaxosmithkline, LLC. | $16.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Weinroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.